Trials / Withdrawn
WithdrawnNCT00664287
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients Deemed Appropriate for Further Lipid Modification.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | niacin (+) laropiprant | Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study. |
| DRUG | placebo (unspecified) | Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-11-01
- First posted
- 2008-04-22
- Last updated
- 2015-04-09
Source: ClinicalTrials.gov record NCT00664287. Inclusion in this directory is not an endorsement.